Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer.

Hdl Handle:
http://hdl.handle.net/10147/314395
Title:
Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer.
Authors:
O'Connor, Anthony; McNamara, Deirdre; O'Moráin, Colm A
Affiliation:
Department of Gastroenterology and Clinical Medicine, Adelaide and Meath Hospital incorporating the National Children's Hospital/Trinity College, Belgard Road, Tallaght, Dublin, Ireland, D24.
Citation:
Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer. 2013, 9:CD009322 Cochrane Database Syst Rev
Journal:
The Cochrane database of systematic reviews
Issue Date:
2013
URI:
http://hdl.handle.net/10147/314395
DOI:
10.1002/14651858.CD009322.pub2
PubMed ID:
24062262
Abstract:
Adenocarcinoma of the stomach is the second leading cause of cancer related death in the world. Gastric intestinal metaplasia (GIM) is a recognised premalignant condition of the stomach. It has been described as occurring in up to one in five patients in western countries. Although there is a definite risk of progression from GIM to cancer, published guidelines and statements differ as to the utility and structure of surveillance programs for this condition.
Item Type:
Article
Language:
en
ISSN:
1469-493X

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connor, Anthonyen_GB
dc.contributor.authorMcNamara, Deirdreen_GB
dc.contributor.authorO'Moráin, Colm Aen_GB
dc.date.accessioned2014-03-21T16:37:50Z-
dc.date.available2014-03-21T16:37:50Z-
dc.date.issued2013-
dc.identifier.citationSurveillance of gastric intestinal metaplasia for the prevention of gastric cancer. 2013, 9:CD009322 Cochrane Database Syst Reven_GB
dc.identifier.issn1469-493X-
dc.identifier.pmid24062262-
dc.identifier.doi10.1002/14651858.CD009322.pub2-
dc.identifier.urihttp://hdl.handle.net/10147/314395-
dc.description.abstractAdenocarcinoma of the stomach is the second leading cause of cancer related death in the world. Gastric intestinal metaplasia (GIM) is a recognised premalignant condition of the stomach. It has been described as occurring in up to one in five patients in western countries. Although there is a definite risk of progression from GIM to cancer, published guidelines and statements differ as to the utility and structure of surveillance programs for this condition.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to The Cochrane database of systematic reviewsen_GB
dc.titleSurveillance of gastric intestinal metaplasia for the prevention of gastric cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Gastroenterology and Clinical Medicine, Adelaide and Meath Hospital incorporating the National Children's Hospital/Trinity College, Belgard Road, Tallaght, Dublin, Ireland, D24.en_GB
dc.identifier.journalThe Cochrane database of systematic reviewsen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.